Authors
Maryam Edalatifard, Maryam Akhtari, Mohammadreza Salehi, Zohre Naderi, Ahmadreza Jamshidi, Shayan Mostafaei, Seyed Reza Najafizadeh, Elham Farhadi, Nooshin Jalili, Masoud Esfahani, Besharat Rahimi, Hossein Kazemzadeh, Maedeh Mahmoodi Aliabadi, Tooba Ghazanfari, Mohammadreza Sattarian, Hourvash Ebrahimi Louyeh, Seyed Reza Raeeskarami, Saeidreza Jamalimoghadamsiahkali, Nasim Khajavirad, Mahdi Mahmoudi, Abdolrahman Rostamian
Publication date
2020/12/1
Journal
European Respiratory Journal
Volume
56
Issue
6
Publisher
European Respiratory Society
Description
Introduction
There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.
Methods
We conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day−1 for 3 days) or standard care alone. The study end-point was the time of clinical improvement or death, whichever came first. Primary and safety analysis was done in the intention-to-treat (ITT) population.
Results
68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020 …
Scholar articles
M Edalatifard, M Akhtari, M Salehi, Z Naderi… - European Respiratory Journal, 2020